H.R. 8370 Would Require a Public FDA Listing for Every US Supplement: What Amazon Sellers Should Know
H.R. 8370 would require every US supplement to be listed with FDA and a number on the label. The bill is not law. What Amazon sellers should do now.
A bill in Congress would require every dietary supplement marketed in the United States to be listed with the Food and Drug Administration, and would put those listings in a public searchable database. The bill is H.R. 8370, the Dietary Supplement Listing Act of 2026. It is a proposal. It has not passed the House or the Senate, and it is not law.
If it became law, Amazon supplement sellers would face two practical changes. First, the person named on the product label would have to file a product listing with FDA and, on a set timetable, print an FDA listing number on the packaging. Second, a public FDA record of the label would make it easier for anyone — including Amazon, competitors, and regulators — to compare that label with the Amazon listing. Mismatches would be easier to spot.
Brightview Strategies will keep tracking this bill and will post updates if it moves.
What the bill is, and where it stands
Rep. Maxine Dexter (D-OR) introduced H.R. 8370 on April 20, 2026, and it was referred the same day to the House Committee on Energy and Commerce. On April 29, 2026, the Energy and Commerce Subcommittee on Health held a legislative hearing that included the bill, along with a large slate of other food and supplement proposals. Congress.gov still lists the bill's status as Introduced. The only formal actions on the all-actions list are the April 20 introduction and referral. The bill has not been reported out of committee and has not passed either chamber.
A Senate version was introduced earlier in 2026 by Sen. Dick Durbin (D-IL). The Council for Responsible Nutrition welcomed the House bill after earlier supporting the Senate introduction, and it has said it wants to work with Rep. Dexter on differences between the two versions. Industry groups are not united. According to NutraIngredients, the Natural Products Association remains opposed to mandatory product listing.
After the November 2026 midterms, NutraIngredients reported that a House Democratic working group's pre-election recommendations for the first 100 days of the next Congress included H.R. 8370. The same article says those recommendations have not been adopted as a formal Democratic caucus agenda. The bill may get more attention, but it is still only a proposal.
What the bill would require
Under the introduced text, every dietary supplement marketed in the United States would have to be listed with FDA. The duty would fall on the "responsible person": the manufacturer, packer, or distributor whose name appears on the label. If that company is a foreign entity, its United States agent would file the listing.
The filing would have to include:
- The product name and statement of identity, including brand name and flavors
- An electronic copy of the label
- A list of all ingredients required to appear on the label, with the amount per serving of each listed dietary ingredient, and the percent of daily value where current labeling rules already require it
- The amount per serving of ingredients inside a proprietary blend, which the bill says "shall remain confidential and not subject to public disclosure"
- The number of servings per container for each container size
- Directions for use
- Warnings, notices, and safe handling statements
- Major food allergen statements
- The product form, such as tablets, capsules, powders, liquids, softgels, or gummies
- Any disease-related claim or structure/function claim that appears on the label or package insert
FDA would assign a dietary supplement product listing number. The bill would also let a responsible person reserve listing numbers before filing. In some cases, one listing could cover more than one SKU, if the products have identical formulations and forms, or the same form and differ only in color, excipients, or flavorings, including different package sizes.
The bill would not give FDA premarket approval authority. A rule of construction in the text says nothing in the new section shall be construed "to grant the Secretary authority to require the approval of a dietary supplement prior to marketing."
If a responsible person failed to file a listing, file a required change, or provide additional information FDA requested, the product would be treated as misbranded under the Federal Food, Drug, and Cosmetic Act.
The bill would also require the responsible person, on FDA's request and within five calendar days, to provide the names and addresses of facilities that manufacture, package, label, or hold the product, and of suppliers of dietary ingredients. That information would stay confidential.
If a product is discontinued, the responsible person would have one year to notify FDA. If listed information that appears on the label changes, the update would have to be filed when the changed product first enters interstate commerce. That matters for reformulations and later label revisions.
When listings and label numbers would be due
The deadlines are more specific than a simple "18 months for existing products, at launch for new ones."
Under the introduced text, the cutoff is January 1, 2027, not the date the bill becomes law:
- For a supplement already offered in interstate commerce on or before January 1, 2027, the listing would be due no later than 18 months after the date of enactment. The listing number would have to appear on the label beginning two years after enactment.
- For a supplement not offered in interstate commerce on or before January 1, 2027, the listing would have to be submitted at the time the product is introduced into interstate commerce, and the listing number would have to be on the label at that same time. As Epstein Becker Green has noted, there would be no grace period for those later launches.
Because the bill is not law, none of these clocks has started. The January 1, 2027 date is still important for planning. If the bill later became law in this form, products that were not on the market by that date would be treated as new products. Sellers planning 2027 launches should watch this cutoff closely.
Within two years of enactment, FDA would have to build a publicly searchable electronic database of listing information, searchable by listing number and by other filed fields. Contact details beyond what is on the label, U.S. agent contact information for foreign companies, and proprietary-blend amounts would stay out of the public database. Product names, the electronic label, ingredients (other than confidential blend amounts), servings, directions, warnings, allergen statements, product form, and claims would be public.
Why this matters for Amazon supplement sellers
A public FDA file of the actual label would make it much easier to compare that label with the Amazon detail page. Titles, bullet points, ingredient claims, warning language, allergen statements, and images of the label would all be checkable against an official record. Amazon already polices supplement listings. A public database would give Amazon, competitors, and regulators a simple way to spot a mismatch.
That is a problem if your Amazon listing promises a formula, a claim, or a warning that does not match the physical label, or if older packaging is still in the photos after a reformulation. It is also a problem if you sell under a private label and the name on the bottle, the Amazon brand name, and the actual formulation are not aligned.
Private-label sellers would feel this in two other ways. If your name is the one on the label, you would be the responsible person and would have to file for each product, and for each later reformulation or label change that updates listed information. You would also have to plan a packaging change so the FDA listing number can be printed on the label, on the timetable above. If a contract manufacturer or another company is the named responsible person, you would still need to know who is filing, and you would still need the listing number on the pack before you can ship new products that fall under the "new product" rule.
You can start the consistency work now. Brightview Strategies built an Amazon Listing Compliance Checker that flags common listing issues. It is not a substitute for a label-to-listing audit, but it is a useful first pass while you line up the physical label, the Supplement Facts panel, and the Amazon page.
What to do now
None of this is required until Congress passes a bill and the president signs it. Still, the work that would be hardest under a short deadline is work many sellers can start without waiting:
- Audit each Amazon listing against the current physical label, including the product title, bullets, A+ content, and images. Make sure ingredients, amounts, claims, directions, warnings, and allergen statements match. Fix mismatches now, rather than after a public FDA record exists.
- Build a simple inventory of every supplement SKU you sell in the United States: brand and product name, flavors, product form, current formula, label version, who is named on the label, and whether that company is foreign and has a U.S. agent.
- Keep formulation and label-change records in one place, so you can file updates if a listing rule takes effect.
- Talk with your packager or label designer about how you would add an FDA listing number to the artwork, and how long a packaging change actually takes for your products.
- If you use a contract manufacturer or a foreign supplier, confirm in writing who would be the responsible person and who would reserve and file listing numbers.
- Do not treat this bill as law, and do not print a listing number you do not have. Watch for movement in Congress, including any changes to the January 1, 2027 cutoff or the label-number deadlines.
Brightview Strategies will keep tracking H.R. 8370 and related proposals, and we will post updates if the bill advances or the requirements change. If you want help reviewing supplement listings for consistency, or building a SKU and label inventory before a rule like this arrives, contact Brightview Strategies.
This post is for general information only and is not legal advice. You should consult a qualified attorney about how any legislation, if enacted, would apply to your products and business.
Selling on Amazon?
Brightview Strategies runs listings, PPC, compliance, and account management for sellers of all kinds of products. First consultation is free.
Get in touchRelated posts
Amazon Now Shows Estimated Lead Times for US FBA Shipments: How to Use Them This Holiday Season
Amazon is adding estimated receive and Prime-eligible lead times to US FBA shipments. What changed, what the numbers mean, and how to plan restocks around them.
Amazon's 2027 FBA Fee Update: What US Sellers Should Check Before January 15
Amazon's November 5 update sets 2027 US FBA fees: a $0.19 average increase on January 15, new storage rules on February 1, and an unchanged fuel surcharge.
GS1 UPCs for Amazon Sellers: Single GTINs, Company Prefixes, and Multipacks
How to choose a $30 single GS1 GTIN or a Company Prefix for Amazon, and why you shouldn't reuse or "change" a single-item UPC for a multipack.